인공심장판막 시장 규모, 점유율, 동향 분석 보고서 : 밸브별, 소재별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Prosthetic Heart Valve Market Summary

The global prosthetic heart valve market size was estimated at USD 9.64 billion in 2024 and is projected to reach USD 20.69 billion by 2033, growing at a CAGR of 8.7% from 2025 to 2033. Rising valvular heart diseases drive the growth of the market.

According to an NCBI article published in December 2024, recent estimates indicate that approximately 54.8 million people are affected by rheumatic heart disease (RHD), with a confidence range between 43.3 and 67.6 million. In addition, non-rheumatic calcific aortic valve disease (CAVD) impacts around 13.3 million individuals, while non-rheumatic degenerative mitral valve disease (DMVD) accounts for approximately 15.5 million cases globally. These conditions are among the leading causes of structural valve deterioration, often necessitating surgical or transcatheter valve replacement. Moreover, the high and growing prevalence of both rheumatic and degenerative valve disorders across diverse age groups and regions is a key factor propelling the expansion of the market.

The rising incidence of heart valve disorders, particularly among the elderly, is a key driver for the growing adoption of prosthetic heart valve procedures, including both surgical and transcatheter approaches. Degenerative conditions such as aortic stenosis and mitral regurgitation are becoming increasingly prevalent, prompting the need for effective interventions like prosthetic valve implants. According to the CDC article published in 2024, three in four adults in the U.S. have limited awareness of heart valve disease, with particularly low recognition among those aged 65 and older, ironically, the group most at risk. Annually, more than 5 million Americans are diagnosed with heart valve disease, and the condition is responsible for over 25,000 deaths each year. These figures underscore a pressing need for improved education, early diagnosis, and expanded access to prosthetic heart valve therapies.

Government funding and awareness campaigns fuel growth in the prosthetic heart valve industry. According to the American Heart Association, Inc., an article published in October 2024, the CDC awarded USD 8.4 million in grants to the American Heart Association to launch national campaigns focused on heart valve disease education. These initiatives will include educational outreach targeting patients, healthcare providers, and women, an underserved high-risk group. The program stems from the bipartisan CAROL Act, signed into law in December 2022, to prioritize HVD research and awareness.

There is an increasing demand for minimally invasive surgeries, including transcatheter valve replacement (TAVR), due to their shorter recovery times, reduced complication risks, and lower overall healthcare costs than traditional open-heart surgery. This shift towards non-invasive procedures is a critical factor propelling the market. In April 2024, Abbott announced FDA approval for its TriClip system, a transcatheter edge-to-edge repair technology for treating tricuspid regurgitation (TR). This first-of-its-kind device allows for less invasive treatment, improving patient outcomes without needing high-risk open-heart surgery. Clinical trials showed significant improvements in TR severity and quality of life for patients treated with TriClip.

Technological advancements in Transcatheter Heart Valves (THV) design, such as enhanced valve durability, ease of implantation, and better patient outcomes, are key drivers driving market growth. Advancements in imaging techniques and valve delivery systems also significantly improve procedural success and expand the patient pool eligible for THV procedures. In August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System received CE mark approval. This state-of-the-art transcatheter aortic valve replacement system features a new valve size to serve patients with larger anatomies. It is indicated for individuals at low, intermediate, and high risk experiencing severe aortic stenosis. The system incorporates a self-expanding design and a refined deployment mechanism, enhancing valve positioning accuracy to improve overall patient outcomes.

Global Prosthetic Heart Valve Market Report Segmentation

This report forecasts revenue growth and analyzes the latest trends in each sub-segments from 2021 to 2033 at the global, regional, and country levels. For this report, Grand View Research has segmented the global prosthetic heart valve market report based on valve, material, end-use, and region:

• Valve Outlook (Revenue, USD Million, 2021 - 2033)
• Transcatheter Heart Valves
• Bioprosthetic (Tissue) Valves
• Homograft's
  • Heterografts
  • Stented
  • Stentless
• Mechanical Valves
  • Tilting Disc Valves
  • Ball Cage Valves
• Material Outlook (Revenue, USD Million, 2021 - 2033)
• Metal Alloys
• Pyrolytic Carbon
• Biological Tissue
• Polymers
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Valve outlook
  • 2.2.2. End Use outlook
• 2.3. Competitive Insights

Chapter 3. Global Prosthetic Heart Valve Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising valvular heart diseases
    • 3.2.1.2. Government funding and awareness campaigns
    • 3.2.1.3. Technological advancements in heart valve
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatments
    • 3.2.2.2. Regulatory challenges and approval delays
• 3.3. Global Prosthetic Heart Valve: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Technology Landscape
• 3.5. Case Study Analysis

Chapter 4. Global Prosthetic Heart Valve Market Segment Analysis, By Valve, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Valve Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Prosthetic Heart Valve Market, by Valve, 2021 to 2033
• 4.5. Transcatheter Heart Valves
  • 4.5.1. Transcatheter heart valves market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Bioprosthetic (Tissue) Valves
  • 4.6.1. Bioprosthetic (Tissue) valves market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.2. Stented
    • 4.6.2.1. Stented market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.3. Heterografts
    • 4.6.3.1. Heterografts market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.4. Stentless
    • 4.6.4.1. Stentless market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6.5. Homografts
    • 4.6.5.1. Homografts market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Mechanical Valves
  • 4.7.1. Mechanical valves market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7.2. Tilting Disc Valves
    • 4.7.2.1. Tilting disc valves market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.2.1.1. CRT-Defibrillator
      • 4.7.2.1.2. CRT-Pacemakers
  • 4.7.3. Ball Cage Valves
    • 4.7.3.1. Ball cage valves market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Prosthetic Heart Valve Market Segment Analysis, By Material, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Material Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Prosthetic Heart Valve Market, by Material, 2021 to 2033
• 5.5. Biological Tissue
  • 5.5.1. Biological tissue market estimates and forecasts, 2021 to 2033 (USD million)
• 5.6. Pyrolytic Carbon
  • 5.6.1. Pyrolytic carbon market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Metal Alloys
  • 5.7.1. Metal alloys market estimates and forecasts, 2021 to 2033 (USD million)
• 5.8. Polymers
  • 5.8.1. Polymers market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Global Prosthetic Heart Valve Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2024 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Prosthetic Heart Valve Market, by End Use, 2021 to 2033
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD million)
• 6.6. Ambulatory Surgery Centers
  • 6.6.1. Ambulatory surgery centers market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts, 2021 to 2033 (USD million)

Chapter 7. Prosthetic Heart Valve Market Segment Analysis, By Region, 2021- 2033 (USD Million)

• 7.1. Regional Market Share Analysis, 2024 & 2034
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Snapshot
• 7.4. Prosthetic Heart Valve Market Share by Region, 2024 & 2033:
• 7.5. North America
  • 7.5.1. North America prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Scenario
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. U.S. prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Scenario
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Canada prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Scenario
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Mexico prosthetic heart valve market, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Scenario
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. UK prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Scenario
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Germany prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Scenario
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. France prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Scenario
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Italy prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Scenario
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Spain prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Scenario
    • 7.6.7.3. Competitive Scenario
    • 7.6.7.4. Norway prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Regulatory Scenario
    • 7.6.8.3. Competitive Scenario
    • 7.6.8.4. Sweden prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Regulatory Scenario
    • 7.6.9.3. Competitive Scenario
    • 7.6.9.4. Denmark prosthetic heart valve market, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Regulatory Scenario
    • 7.7.1.3. Competitive Scenario
    • 7.7.1.4. Japan prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Scenario
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. China prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Scenario
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. India prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Regulatory Scenario
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. Australia prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Regulatory Scenario
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. South Korea prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Regulatory Scenario
    • 7.7.6.3. Competitive Scenario
    • 7.7.6.4. Thailand prosthetic heart valve market, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Regulatory Scenario
    • 7.8.1.3. Competitive Scenario
    • 7.8.1.4. Brazil prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Scenario
    • 7.8.2.3. Competitive Scenario
    • 7.8.2.4. Argentina prosthetic heart valve market, 2021 - 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key Country Dynamics
    • 7.9.1.2. Regulatory Scenario
    • 7.9.1.3. Competitive Scenario
    • 7.9.1.4. South Africa prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Regulatory Scenario
    • 7.9.2.3. Competitive Scenario
    • 7.9.2.4. Saudi Arabia prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Regulatory Scenario
    • 7.9.3.3. Competitive Scenario
    • 7.9.3.4. UAE prosthetic heart valve market, 2021 - 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Regulatory Scenario
    • 7.9.4.3. Competitive Scenario
    • 7.9.4.4. Kuwait prosthetic heart valve market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Profiles
  • 8.3.1. Edwards Lifesciences
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Valve benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Medtronic plc
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Valve benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Abbott Laboratories
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Valve benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Boston Scientific Corp.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Valve benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. CryoLife, Inc. (now Artivion)
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Valve benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. MicroPort Scientific Corp.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Valve benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Lepu Medical Technology(Beijing)Co.,Ltd.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Valve benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Venus Medtech (Hangzhou) Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Valve benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Foldax, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Valve benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Meril Life Sciences
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Valve benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. TTK Healthcare Limited
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Valve benchmarking
    • 8.3.11.4. Strategic initiatives